Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies

Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks.

On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. Presenting the results at the 2026 American Society of Clinical Oncology meeting, in TNBC, Iza-bren delivered a median overall survival of 15.9 months as compared to 12.5 months and progression-free survival of 8.5 months versus 3.1 months. It improved the confirmed objective response rate to 51.7% versus 20.5% compared with the physician’s choice of chemotherapy.

Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies

In esophageal cancer, SystImmune said iza-bren posted a median overall survival of 9.8 months compared to 7.2 months and progression-free survival of 4.2 months versus 2.0 months. It raised the objective response rate to 35.3% from 13.1%. The companies said safety remained manageable, with predominantly hematologic adverse events and low interstitial lung disease rates.

Bristol-Myers Squibb Company (NYSE:BMY) is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.